Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.


Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
01 2019
Historique:
received: 08 05 2018
accepted: 18 10 2018
pubmed: 5 12 2018
medline: 11 5 2019
entrez: 5 12 2018
Statut: ppublish

Résumé

Infiltration of human cancers by T cells is generally interpreted as a sign of immune recognition, and there is a growing effort to reactivate dysfunctional T cells at such tumor sites

Identifiants

pubmed: 30510250
doi: 10.1038/s41591-018-0266-5
pii: 10.1038/s41591-018-0266-5
doi:

Substances chimiques

Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-94

Références

Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
doi: 10.1126/science.aar4060
Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
doi: 10.1126/science.1129139
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
doi: 10.1056/NEJMoa020177
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
doi: 10.1126/science.aaa8172
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
doi: 10.1038/nature13954
Le, D. T. et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
doi: 10.1056/NEJMoa1500596
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
doi: 10.1126/science.aaa1348
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
doi: 10.1056/NEJMoa1200694
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
doi: 10.1038/nature21349
Andersen, R. S. et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642–1650 (2012).
doi: 10.1158/0008-5472.CAN-11-2614
Bobisse, S. et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8 (+) T cells in immunotherapy-naive ovarian cancer. Nat. Commun. 9, 1092 (2018).
doi: 10.1038/s41467-018-03301-0
Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8
doi: 10.1126/scitranslmed.3008918
Kvistborg, P. et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1, 409–418 (2012).
doi: 10.4161/onci.18851
Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387–1390 (2015).
doi: 10.1126/science.aad1253
van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439–e442 (2013).
doi: 10.1200/JCO.2012.47.7521
Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
doi: 10.1038/s41586-018-0130-2
Pasetto, A. et al. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol. Res. 4, 734–743 (2016).
doi: 10.1158/2326-6066.CIR-16-0001
Gros, A. et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014).
doi: 10.1172/JCI73639
Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433–438 (2016).
doi: 10.1038/nm.4051
Dahlin, A. M. et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod. Pathol. 24, 671–682 (2011).
doi: 10.1038/modpathol.2010.234
Sato, E. et al. Intraepithelial CD8
doi: 10.1073/pnas.0509182102
Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44–55 (2014).
doi: 10.1158/1078-0432.CCR-13-0945
Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400–404 (2012).
doi: 10.1038/nature10755
Verdegaal, E. M. et al. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature 536, 91–95 (2016).
doi: 10.1038/nature18945
McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017).
doi: 10.1016/j.cell.2017.10.001
Webb, J. R., Milne, K., Kroeger, D. R. & Nelson, B. H. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 141, 293–302 (2016).
doi: 10.1016/j.ygyno.2016.03.008
Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).
doi: 10.1053/j.gastro.2011.07.050
Tang, F. et al. RNA-Seq analysis to capture the transcriptome landscape of a single cell. Nat. Protoc. 5, 516–535 (2010).
doi: 10.1038/nprot.2009.236
Bolotin, D. A. et al. MiTCR: software for T-cell receptor sequencing data analysis. Nat. Methods 10, 813–814 (2013).
doi: 10.1038/nmeth.2555
Linnemann, C. et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat. Med. 19, 1534–1541 (2013).
doi: 10.1038/nm.3359
Ochi, T. et al. Optimization of T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy. Cancer Immunol. Res. 3, 1070–1081 (2015).
doi: 10.1158/2326-6066.CIR-14-0222
Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123–128 (2010).
doi: 10.1038/nm.2071
Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4
doi: 10.1038/nm.3773
Gelman, A. et al. Bayesian Data Analysis. (CRC Press, Boca Raton, 2014). .

Auteurs

Wouter Scheper (W)

Division of Molecular Oncology & Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Sander Kelderman (S)

Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Lorenzo F Fanchi (LF)

Division of Molecular Oncology & Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Carsten Linnemann (C)

Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Gavin Bendle (G)

Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Marije A J de Rooij (MAJ)

Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Christian Hirt (C)

Department of Biomedicine, University of Basel, Basel, Switzerland.

Riccardo Mezzadra (R)

Division of Molecular Oncology & Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Maarten Slagter (M)

Division of Molecular Oncology & Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Krijn Dijkstra (K)

Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Roelof J C Kluin (RJC)

Central Genomics Facility, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Petur Snaebjornsson (P)

Division of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Katy Milne (K)

Trev and Joyce Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.

Brad H Nelson (BH)

Trev and Joyce Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.

Henry Zijlmans (H)

Department of Gynecologic Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Gemma Kenter (G)

Department of Gynecologic Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Emile E Voest (EE)

Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

John B A G Haanen (JBAG)

Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Ton N Schumacher (TN)

Division of Molecular Oncology & Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands. t.schumacher@nki.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH